OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
Kathryn Evans(Women's & Children's Health Research Institute), Richard B. Lock(Cancer Institute of New South Wales), Lisa McDermott(Women's & Children's Health Research Institute), Cara E. Toscan(Women's & Children's Health Research Institute), Tillman Pearce, Fanying Meng(Shanghai University), Beverly A. Teicher(National Cancer Institute), Kathryn G. Roberts(St. Jude Children's Research Hospital), Malcolm A. Smith(National Cancer Institute), Charles G. Mullighan(St. Jude Children's Research Hospital), Chelsea Mayoh(Cancer Institute of New South Wales), Komal S. Rathi(Children's Hospital of Philadelphia), Yuelong Guo(RTI International), Tara Pritchard(Women's & Children's Health Research Institute), Stephen W. Erickson(RTI International), Narimanne El-Zein(Women's & Children's Health Research Institute), Connor Jones(Women's & Children's Health Research Institute), Chi‐Sheng Shia(Efficient Pharma Management (Taiwan)), Donald Jung(Anshan Hospital), Zhaohui Gu(City of Hope)
Cited by 53
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934